Since TZT activates both GIP and GLP-1, it induces remarkable body weight reduction, unlike GIPR agonists, which are implicated in the development of obesity when used alone
Elevated GH levels subsequently trigger the liver to produce insulin-like growth factor 1 (IGF-1), which mediates many of GH's anabolic effects, including protein synthesis, lipolysis (fat breakdown), and tissue repair
This makes it a popular choice among individuals looking to support concentration, alertness, and cognitive resilience during demanding days or periods of fatigue
One dose per week
Bioglutide (NA-931) presents a novel quadruple-agonist mechanism that is scientifically ambitious, targeting GLP-1, GIP, glucagon, and IGF-1 receptors in a single oral molecule
[CrossRef] [PubMed] [Google Scholar] Why does obesity cause diabetes